Greenwich Lifesciences Inc (GLSI)
Greenwich LifeSciences, Inc. is a clinical-stage biopharmaceutical company focused on developing cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead candidate, GP2, is being studied in a Phase III trial aimed at helping prevent breast cancer recurrence in patients who have already had surgery. The company is also advancing FLAMINGO-01, a Phase III study evaluating GLSI-100, which combines GP2 and GM-CSF, in HER2-positive breast cancer patients. Founded in 2006 and headquartered in Stafford, Texas, Greenwich LifeSciences changed its name from Norwell, Inc. in 2018. Its common stock trades on NASDAQ under the symbol GLSI.
Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Market Outlook FAQ
Jump directly to the stock analysis sections supported by the latest available data.
Data update note:
Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Dividend Yield | Next Earnings Date | Price-to-Book Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-GLSI
|
$13.06
|
-32.9% Downside
|
Overvalued
|
$57
|
192.6% Upside
|
Bargain
|
Weak
|
0.0%
|
November 16, 2026
|
87.6x
|
285.9 M
|
264.1 M
|
0.0%
|
52.1%
|
5.2
|
55.6%
|
